Logo

PharmaShots Weekly Snapshots (April 18-22, 2022)

Share this
PharmaShots Weekly Snapshots (April 18-22, 2022)

PharmaShots Weekly Snapshots (April 18-22, 2022)

Novavax Initiates NVX-CoV2373 (COVID-19 vaccine booster) in P-III (PREVENT-19) Trial for COVID-19 in Adolescents

Published: Apr 22, 2022 | Tags: Novavax, NVX-CoV2373, COVID-19, Vaccine Booster, P-III, PREVENT-19 Trial, COVID-19, Adolescents

Sanofi Entered into a License Agreement with Terran Biosciences for Two Late-Stage CNS pipeline Assets to Treat Neurological and Psychiatric Indications

Published: Apr 22, 2022 | Tags: Sanofi, Terran Biosciences, CNS Pipeline Assets, Neurological, Psychiatric Indications

Novavax Reports Results of COVID-19-Influenza Vaccine in P-I/II Trial for the Treatment of COVID-19

Published: Apr 22, 2022 | Tags: Novavax, COVID-19-Influenza Vaccine, P-I/II Trial, COVID-19

Orasis Reports Results of CSF-1 in P-III (NEAR-1 & 2) Trials for the Treatment of Presbyopia

Published: Apr 22, 2022 | Tags: Orasis, CSF-1, P-III, NEAR-1 & 2 Trials, Presbyopia

Zambon’s CMS I-neb Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of Non-Cystic Fibrosis Bronchiectasis

Published: Apr 22, 2022 | Tags: Zambon, CMS I-neb, US, FDA, Breakthrough Therapy Designation, Non-Cystic Fibrosis Bronchiectasis

Dragonfly Expands its 2019 Collaboration with AbbVie to Develop Novel Therapies for Immune-Mediated Diseases

Published: Apr 22, 2022 | Tags: Dragonfly, 2019, AbbVie, Therapies, Immune-Mediated Diseases

Servier Publishes Results of Tibsovo (ivosidenib) in P-III (AGILE) Trial for IDH1-Mutated Acute Myeloid Leukemia in NEJM

Published: Apr 21, 2022 | Tags: Servier, Tibsovo, ivosidenib, P-III, AGILE Trial, IDH1-Mutated, Acute Myeloid Leukemia, NEJM

Ultragenyx Reports the First Patient Dosing of Setrusumab (UX143) in P-II/III (Orbit) Study for the Treatment of Osteogenesis Imperfecta

Published: Apr 21, 2022 | Tags: Ultragenyx, Setrusumab, UX143, P-II/III, Orbit Study Osteogenesis Imperfecta

Otonomy Reports Results of OTO-413 in P-IIa Clinical Trial for the Treatment of Hearing Loss

Published: Apr 21, 2022 | Tags: Otonomy, OTO-413, P-IIa, Clinical Trial, Hearing Loss

AstraZeneca Reports Results of Evusheld in P-III (PROVENT) Trial for the Treatment of Symptomatic COVID-19

Published: Apr 21, 2022 | Tags: AstraZeneca, Evusheld, P-III, PROVENT Trial, Symptomatic COVID-19

Vertex Receives the Health Canada Marketing Authorization for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat Cystic Fibrosis

Published: Apr 21, 2022 | Tags: Vertex, Health Canada, Marketing Authorization, Trikafta, elexacaftor, tezacaftor,ivacaftor, Cystic Fibrosis

Boehringer Ingelheim Entered into a Research Agreement with VantAI to Identify Novel Protein Degraders

Published: Apr 21, 2022 | Tags: VantAI, Boehringer Ingelheim, Novel Protein Degraders, Geometric Deep Learning Platform

AlloVir’s Posoleucel Receives the US FDA’s RMAT Designation for Prevention of Multiple Infections from 6 Viruses in Patient with Allogeneic Hematopoietic Cell Transplant

Published: Apr 20, 2022 | Tags: AlloVir, Posoleucel, US, FDA, RMAT, Designation, Allogeneic Hematopoietic Cell Transplant

Idorsia Launches Pivlaz (clazosentan) for the Treatment of Aneurysmal Subarachnoid Hemorrhage in Japan

Published: Apr 20, 2022 | Tags: Idorsia, Pivlaz, clazosentan, MHLW, Approval, Aneurysmal Subarachnoid Hemorrhage, Japan

Bavarian Nordic Reports the First Patient Dosing in P-III (VANIR) Trial for the Treatment of Respiratory Syncytial Virus

Published: Apr 20, 2022 | Tags: Bavarian Nordic, P-III, VANIR Trial, Respiratory Syncytial Virus

INmune Bio Reports First Patient Dosing in P-II (XPro1595) Trial for the Treatment of Neuroinflammation in Patients with Alzheimer Disease

Published: Apr 20, 2022 | Tags: INmune Bio, P-II, XPro1595 Trial, Neuroinflammation, Alzheimer Disease

SpringWorks Entered into a Clinical Trial Collaboration and Supply Agreement with Regeneron to Evaluate Nirogacestat + REGN5458 for Multiple Myeloma

Published: Apr 20, 2022 | Tags: SpringWorks, Regeneron, Nirogacestat, REGN5458, Multiple Myeloma

Ono Entered into an Agreement with Domain and Université de Montréal to Discover Small Molecules Targeting G-Protein Coupled Receptors

Published: Apr 20, 2022 | Tags: Ono, Domain, Université de Montréal, Small Molecules, G-Protein Coupled Receptors

Neuraly Reports the Completion of Patient Enrollment in P-II Study of NLY01 for the Treatment of Parkinson’s Disease

Published: Apr 19, 2022 | Tags: Neuraly, P-II Study, NLY01, Parkinson’s Disease

BeiGene Provides Updates of Tislelizumab in P-III (RATIONALE-309) Trial as 1L Treatment of Recurrent or Metastatic Nasopharyngeal Cancer Presented at ASCO 2022

Published: Apr 19, 2022 | Tags: BeiGene, Tislelizumab, P-III, RATIONALE-309 Trial, Nasopharyngeal Cancer, ASCO, 2022

Daiichi Sankyo and AstraZeneca Report the US FDA Acceptance for Priority Review of Enhertu to Treat HER2 Mutant Metastatic Non-Small Cell Lung Cancer

Published: Apr 19, 2022 | Tags: Daiichi Sankyo, AstraZeneca, US, FDA, Enhertu, Priority Review, HER2 Mutant, Metastatic, Non-Small Cell Lung Cancer

Takeda’s Nuvaxovid COVID-19 Vaccine Receives the MHLW Approval for the Treatment of COVID-19

Published: Apr 19, 2022 | Tags: Takeda, Nuvaxovid, COVID-19 Vaccine, MHLW, Approval, COVID-19

Amgen Reports Results of ABP 654 (biosimilar, ustekinumab) in P-III Study for the Treatment of Plaque Psoriasis

Published: Apr 19, 2022 | Tags: Amgen, ABP 654, biosimilar, ustekinumab, P-III Study, Plaque Psoriasis

Biocytogen Entered into an Agreement with CtM Biotech to Co-develop TCR-Mimic Antibody-Based Multi-Specific T Cell Engagers for Cancer

Published: Apr 19, 2022 | Tags: Biocytogen, CtM Biotech, TCR-Mimic, Antibody-Based, Multi-Specific, T Cell, Engagers, Cancer

Black Diamond Report First Patient Dosing in a P-I Study of BDTX-1535 for Glioblastoma and Non-Small Cell Lung Cancer

Published: Apr 18, 2022 | Tags: Black Diamond, First Patient Dosing, P-I Study, BDTX-1535,  Glioblastoma, Non-Small Cell Lung Cancer

Evelo Reports the Clinical Hold on EDP1867 Program for the Treatment of Atopic Dermatitis

Published: Apr 18, 2022 | Tags: Evelo, Clinical Hold, EDP1867, Program, Atopic Dermatitis

The US FDA Extends BLA Review for Regeneron’s REGEN-COV for the Treatment and Prophylaxis of COVID-19

Published: Apr 18, 2022 | Tags: US, FDA, BLA, Regeneron, REGEN-COV, COVID-19

The US FDA Approved First Breathalyzer to Detect COVID-19

Published: Apr 18, 2022 | Tags: US, FDA, Approved, Breathalyzer, Detect, COVID-19, EUA, InspectIR

TG Therapeutics Voluntary Withdrawal BLA/sNDA of U2 for Patients with CLL and SLL

Published: Apr 18, 2022 | Tags: TG Therapeutics, Voluntary Withdrawal, BLA, sNDA, U2, CLL, SLL, ublituximab, Ukoniq

BeiGene’s Tislelizumab Receives the NMPA’s Approval as a 2L Treatment for Esophageal Squamous Cell Carcinoma

Published: Apr 18, 2022 | Tags: BeiGene, Tislelizumab, NMPA, Approval, 2L, Esophageal Squamous Cell Carcinoma

Related Post: PharmaShots Weekly Snapshots (April 11-15, 2022)

 

 


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions